Sight Sciences to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
Sight Sciences, Inc. (Nasdaq: SGHT), an innovative eyecare technology company, announced its participation in the Inaugural Gilmartin Group Emerging Growth Company Showcase, scheduled for August 31, 2022, at 2:30 PM ET. The event will be held virtually, and interested parties can access a live webcast through the provided link. An archived version will be available on the company's website post-event. Sight Sciences focuses on developing minimally invasive solutions for prevalent eye diseases, including the OMNI Surgical System and TearCare System, aimed at improving patient care.
- None.
- None.
MENLO PARK, Calif., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to present on Wednesday, August 31, 2022, at 2:30pm ET.
Interested parties can access a live webcast of the presentation directly by following this link. An archived webcast of the presentation will be available on the “Investors” section of the Sight Sciences website at https://www.sightsciences.com/ following the event.
Those parties interested in registering for the Inaugural Gilmartin Group Emerging Growth Company Showcase may do so by following this link.
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
For more information, visit www.sightsciences.com.
OMNI® and TearCare® are registered trademarks of Sight Sciences.
SION™ is a trademark of Sight Sciences.
© 2022 Sight Sciences. All rights reserved.
Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com
FAQ
What is the date and time of Sight Sciences' presentation at the Gilmartin Group Emerging Growth Company Showcase?
How can I access the webcast of Sight Sciences' presentation?
What innovations does Sight Sciences focus on in eyecare?
Where can I find the archived presentation of Sight Sciences after the event?
What is the stock symbol for Sight Sciences?
